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Mesenchymal cell movement is normally constrained;
however, ¢bronectin can provide a pathway for stromal
cell migration during embryogenesis, morphogenesis,
and wound healing. Cells can adhere to ¢bronectin via
integrin and nonintegrin receptors, which bind multi-
ple unique peptide sequences. Synthetic peptides and
recombinant proteins were used to delineate the func-
tional domains needed for human ¢broblast migration
over ¢bronectin. The 9th and 10th ¢bronectin type III
repeats, which contain RGD and PHSRN synergy cell
attachment sequences, support almost maximal ¢bro-
blast attachment, but not migration of primary dermal
¢broblasts. Speci¢c sequences within the heparin do-
main and the IIICS region are also required for migra-
tion.These ¢ndings predict and additional data con¢rm
the necessity for the cooperation of multiple integrin
and nonintegrin receptors for ¢broblast migration on ¢-
bronectin. Such stringency of migration most likely
imposes an immense constraint on normal mesenchymal
cell mobility in unperturbed tissue. Loss of such restraint
may be critical for the migration cancer cells through the
extracellular matrix. Keywords: cell migration/wound healing/
a4b1/25b1. J Invest Dermatol 121:695 ^705, 2003
F
ibroblasts of normal stroma in adult animals are rela-
tively stationary despite the absence of architectural
boundaries such as basement membranes. Locomotor
restraint of these mesenchymal cells is released during
embryogenesis, morphogenesis, cancer metastasis, and
wound healing.We have used cutaneous wound repair as a para-
digm to investigate the requisites for adult human ¢broblast
migration.
Approximately 4 d after tissue injury ¢broblasts invade the ¢-
brin clot in the wound space (McCarthy et al, 1988; Iida et al,
1992). Previously, we have demonstrated that ¢broblast activation
is required for invasion of the wound clot (McClain et al, 1996).
At least in part, this activation appears to be a switch from cell
surface receptors that bind type I collagen to those that bind pro-
visional matrix proteins such as ¢brin and ¢bronectin (Gailit
et al, 1996; Xu and Clark, 1996). Furthermore, using an in vitro
wound healing model, we have demonstrated that ¢bronectin,
which is present in a clot at approximately a 1:10 molar ratio with
¢brin, is required for ¢broblast transmigration from a three-di-
mensional type I collagen gel into a three-dimensional ¢brin gel
(Greiling and Clark, 1997). Now we demonstrate that ¢bronectin
is deposited in the periwound connective tissue just before me-
senchymal migration into the wound space and that multiple
¢bronectin domains are required for primary human dermal ¢-
broblast migration on ¢bronectin.
Fibronectin is composed of three general types of homologous
repeating units, termed types I, II, and III (Yamada, 1991), which
are arranged into protease-resistant domains. The central cell-
binding domain (C) is composed of the ¢bronectin type III
repeats and includes an Arg-Gly-Asp-Ser (RGDS) site in repeat
III10 (Ruoslahti, 1988). Synthetic peptides containing this se-
quence block the attachment of some cells to ¢bronectin
(Pierschbacher and Ruoslahti, 1984; Yamada and Kennedy, 1984;
Hautanen et al, 1989). Furthermore, deletion of the RGD sequence
eliminates, and deletion of a nearby PHSRN sequence in repeat
III9 profoundly reduces, cell attachment to ¢bronectin (Obara
et al, 1988). The RGD sequence interacts with several cell surface
integrins, the major one being a5b1 (Pytela et al, 1985; Ruoslahti
and Pierschacher, 1987). Integrins are a family of heterodimeric,
transmembrane, glycoprotein receptors, each consisting of an
a- and a b-subunit (Hynes, 1992).
Although the RGD sequence is clearly important for cell attach-
ment to ¢bronectin, at least ¢ve additional peptide sequences
in the adjacent heparin-binding domain (Hep) (McCarthy
et al, 1988; Iida et al, 1992) have been shown to interact with at least
two distinct classes of cell surface receptors, the a4b1 integrin
(Mould and Humphries, 1991), and membrane-associated proteo-
glycans, such heparan sulfate proteoglycan (HSPG) and chon-
droitin sulfate proteoglycan (CSPG) (McCarthy et al, 1990;
Barkalow and Schwarzbauer, 1991, 1994; Drake et al, 1992; Iida
et al, 1992;Woods et al, 1993). Cell types that use sites within the
heparin domain for attachment include melanoma cells, melano-
cytes, and neuronal cells (Drake et al, 1992; McCarthy et al, 1990;
Iida et al, 1992). In addition, normal human dermal ¢broblast have
been shown to require a site within the heparin region for the
organization of focal contacts (Woods et al, 1993).
A third cell-binding domain is located within the variably
spliced type III connecting segment (abbreviated either V or
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IIICS). In this region two sites, CS1 and CS5, have been identi¢ed
(Humphries et al, 1987; Wayner and Kovach, 1992), which are re-
cognized by a4b1 (Wayner et al, 1989; Guan and Hynes, 1990).
Prior studies have demonstrated that only one of these unique
domains is required for the migration of certain embryonic, can-
cer or epithelial cells (Akiyama et al, 1995; Nagai et al, 1991; Moor-
adian et al, 1993; Mould et al, 1994; Ramos and DeSimone, 1996).
In contrast to studies on ¢broblast cell lines that demonstrated
that only repeats III9 and III10 or RGD clusters are necessary for
migration (Akiyama et al, 1995, 1989; Maheshwari et al, 2000),
respectively, this study demonstrates that multiple domains are
required for primary human dermal ¢broblast migration on
¢bronectin.
MATERIALS AND METHODS
Materials Recombinant platelet-derived growth factor BB (PDGF-
BB) was a gift from C. Hart (ZymoGenetics, Seattle, WA). Fibronectin
and thrombin were provided by G. Marx (New York Blood Center,
New York, NY). Fibronectin was 99% pure and intact by silver-stained
PAGE. Bovine serum albumin (BSA; fatty-acid-free, fraction V) was ob-
tained from Miles (Kankakee, IL). The chymotrysin digestion fragment
of ¢bronectin (FN-120) was obtained from Gibco (Rockville, MD).
Fibronectin peptide CS1 (EILDVPST) and CS1i (i¼ inactive, EILEVPST)
(Humphries et al, 1987; Komoriya et al, 1991) were purchased from Peninsula
Laboratories Inc. (Belmont, CA). Fibronectin peptide I (YEKPGSPPREV
VPRPRPGV) and scrambled peptide I (PEVVPPPVGPRPKRGRYSE)
(McCarthy et al, 1988, 1990); peptide II (KNNQKSEPLIGRKKT) and
scrambled peptide II (LQEPKISTKNKGNRK) (McCarthy et al, 1988,
1990); peptide III (YRVRVTPKEK TGPMKE) and scrambled peptide III
(MKGKVTREVRYPTKPE) (Iida et al, 1992); peptide IV (SPPRRARVT),
a LL for RR substituted peptide IV (SPPLLARVT), and scrambled peptide
IV (RVPRSTPAR) (Mooradian et al, 1993); peptide V (WQPPRARI) and
scrambled peptide V (RQAPRIPW) (Mooradian et al, 1993); and CS5
(GEEIQIGHIPREDIDYHLYP) (Humphries et al, 1987; Mould et al, 1991)
were synthesized by SynPep (Dublin, CA). The purity of all peptides was
higher than 97%.
Human ¢brinogen was obtained from Calbiochem (San Diego, CA). To
prevent ¢brinolysis, plasminogen was removed from the ¢brinogen by
passage through a lysine^Sepharose 4B column (Pharmacia, Piscataway,
NJ) (Deutsch and Mertz, 1970). To remove any contaminating ¢bronectin,
plasminogen-depleted ¢brinogen was further passed through a gelatin^
Sepharose 4B column (Pharmacia) (Engvall and Ruoslahti, 1977). The
removal of ¢bronectin was con¢rmed by SDS^PAGE and ELISA.
Clottability after treatment with lysine^Sepharose 4B and gelatin^
Sepharose 4B was over 90%. Tissue culture £asks were from Costar
(Cambridge, MA), and 24-well tissue culture plates for all migration
assays were from Becton-Dickinson (Lincoln Park, NJ).
Anti-a3 antibody (clone P1B5) (Wayner and Carter, 1987; Wayner et al,
1988) was purchased from Gibco BRL. Antibodies against a4 (clone P4G9)
(Wayner et al, 1989; Massia and Hubbell, 1992), HLA (mAb 1280) and
vinculin (mAb 1624) were from Chemicon (Temecula, CA). Rabbit anti-
¢bronectin was obtained from Dako (Carpinteria, CA). Rabbit anti-
¢brinogen and alkaline-phosphatase-conjugated goat anti-rabbit antibody
were purchased from Cappel/Organon Teknika (Durham, NC). All
experiments on animals and human tissue were approved by the
compliance o⁄ce at SUNY Stony Brook.
Porcine cutaneous wound model Full-thickness excisional wounds
were made by an 8-mm circular punch into the paravertebral skin of
Minipigs. The wounds were dressed with Tegaderm, a polyurethane
occlusive dressing, and harvested 1 and 3 d later as previously described
(Welch et al, 1990).
Specimens from all wound sites were ¢xed in formalin, para⁄n
embedded, sectioned at 5 mm, and stained with Masson trichrome to
delineate morphologic alterations. For immunohistochemistry the
depara⁄nized sections were ¢rst incubated with 0.4% pepsin in 0.1 M
HCl (Folkvord et al, 1989). Nonspeci¢c antibody binding was blocked
with 2% skim milk. Sections were incubated with the primary antibody
(anti¢bronectin or anti¢brinogen, diluted 1:1000 in phosphate-bu¡ered
saline (PBS)) overnight at 41C, followed by a 1.5-h incubation with alkaline-
phosphatase-conjugated anti-rabbit immunoglobulin (diluted 1:600 in
PBS) at room temperature. Sections were then covered with Fast Red
(BioGenex, San Ramon, CA) until red stain developed and
counterstained with Mayer hematoxylin (Sigma, St. Louis, MO).
Cell culture Primary cultures of human adult dermal ¢broblasts (a
gift from Marcia Simon, Living Skin Bank, SUNY at Stony Brook)
were cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM, Life
Technologies) containing 42 mM sodium bicarbonate, 100 U/mL penicillin,
100 mg/mL streptomycin, and 10% fetal bovine serum (HyClone, Logan,
UT) at 371C and 5% CO2/95% air in an humidi¢ed atmosphere. The cells
were used between passages 4 and 12. HT-1080 cells were acquired from
American Type Culture Collection (Rockville, MD) and also cultured in
DMEM containing 42 mM sodium bicarbonate, 100 U/mL penicillin,
100 mg/mL streptomycin, and 10% fetal bovine serum at 371C and 5%
CO2/95% air in an humidi¢ed atmosphere.
Attachment assay Each well of 24-well tissue culture plates (Becton-
Dickinson) was coated with 120 nM intact ¢bronectin, FN-120, or one of
several recombinant ¢bronectin fragments (Barkalow and Schwarzbauer,
1991, 1994). Each chain of the ¢bronectin dimer contains one cell and one
Hep-binding domain; therefore, because domain equivalency was desired,
the molecular weight of a single chain (B250,000 kDa) was used to
calculate molar concentrations of ¢bronectin. Aliquots (450 mL) of these
proteins in DMEM were added to the appropriate wells. After 2 h of
incubation at 371C in 5% CO2, plates were dried overnight at room
temperature under sterile conditions. The next day plates were washed
once with PBS and incubated with 2% BSA for 1 h at 371C to block
nonspeci¢c binding sites.
The assay for measuring ¢broblast attachment to matrix proteins was
performed essentially as described (Gailit et al, 1993) except that the cell
number added to plates was lowered to 10,000 cells per well. In all
experiments cells were allowed to attach for 60 min at 371C before
unattached cells were washed away and attached cells were ¢xed with 2%
glutaraldehyde. After ¢xation, attached cells were air dried at room
temperature and then 100 mL of 0.1% crystal violet in 0.2 M boric acid,
pH 9, was added to each well and the microtiter plate was shaken at 600
rpm on a plate mixer for 20 min. (The staining solution was prepared fresh
from a stock solution of 5% crystal violet in 20% methanol.) Excess stain
was removed by three washes with water. Stained cells were again air-dried
before the crystal violet was solubilized by adding 100 mL of 10% acetic
acid to each well and then shaking the plate at 600 rpm for 20 min.
Absorbance at 590 nm was measured with a dual-wavelength microtiter
plate reader (THERMOmax, Molecular Devices, Menlo Park, CA) and
that reading was corrected for light scattering by subtraction of the
absorbance at 450 nm.
Cytoimmunochemistry of adherent cells After cells were allowed to
adhere to either 120 nM FN-120 or intact ¢bronectin for various time
periods, they were ¢xed in 10% formaldehyde in PBS and then
permeabilized with 0.4% Triton in PBS. Visualization of actin ¢bers and
focal contacts was accomplished by incubating cells ¢rst with mouse
monoclonal antivinculin antibody (Chemicon) followed by and FITC-
conjugated sheep anti-mouse IgG in conjunction with TRITC-conjugated
phalloidin as previously described (Chrzanowska-Wodnicka and Burridge,
1996). Stained specimens were observed and photographed using a Nikon
Microphot FXA epi£uorescence microscope equipped with a Nikon FX-
35DX 35-mm camera.
Migration assays Outmigration and transmigration assays were per-
formed as previously described (Greiling and Clark, 1997).
Outmigration assay Fibroblast cultures harvested at 80% con£uence were
washed twice with DMEMþ 2% BSA and resuspended at a concentration
of 1106 cells/mL. Fibroblasts were mixed with neutralized collagen (Vi-
trogen 100, Celtrix Laboratories, Santa Clara, CA), 2% BSA, 30 ng/mL
PDGF-BB, and 30 mg/mL ¢bronectin in DMEM. A total of 600 mL of
1105 cells suspended in approximately 2 mg/mL collagen was added to
the wells of a 24-well tissue culture plate, pre-coated with 2% BSA. After
2 h of incubation, gels were gently detached from the plastic surface to al-
low contraction. A quantity of 0.5 mL of DMEM with 2% BSA and 30
ng/mL PDGF-BB was added to each well, and gels were incubated over-
night at 371C in 5% CO2. Another set of plates was coated with proteins as
described under ‘‘Attachment assay.’’ After washing the plate three times
with PBS, contracted collagen gel constructs were attached to the coated
plates. DMEM, 2% BSA, and 30 ng/mL PDGF-BB were added to assay
plates so that the medium was level with the top of the collagen gel. Plates
were incubated at 371C in 5% CO2 and 100% humidity for 24 h.
Transmigration assay For three-dimensional transmigration assays, dried
¢brin ¢bril-coated dishes were washed once with PBS, and contracted
collagen gels were placed on the surface. Fibrinogen, ¢bronectin, and
PDGF-BB were mixed with DMEM at a ¢nal concentrations of 300 mg/mL,
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30 mg/mL, and 30 ng/mL, respectively, and then 1.0 U/mL thrombin was
added and the clotting solution cast around the collagen gels. When
needed, other materials such synthetic peptides were added to the mixture.
The collagen gels were surrounded with the ¢brinogen solution so that the
¢brin gel was level with the top of the collagen gel. Plates were incubated
at 371C in 5% CO2 and 100% humidity for 24 h.
Cell quanti¢cation for outmigration and transmigration assays The number of
migrated cells was quanti¢ed under a Nikon inverted-phase microscope by
visually counting identi¢able cell nuclei located outside of the contracted
collagen gel in the ¢brin gel (transmigration assay) or on the matrix (outmi-
gration assay).Within a given experiment each condition was run in tripli-
cate and means7SD were calculated. All experiments were repeated at least
three times. Previous studies (Greiling and Clark, 1997) demonstrated that
cell proliferation did not contribute to cell number after a 24-h incubation.
Videomicroscopy migration assay Plates were coated with proteins, washed
with PBS, and incubated with 2% BSA for 1 h at 371C to block nonspeci¢c
binding sites. After the plates were washed three times with PBS, 40,000
¢broblasts in 3 mL of CO2-independent medium (Life Technologies)
plus the appropriate biologic modi¢er were added. Cell movement was
recorded using a Nikon Diaphot-TMD inverted microscope, equipped
with an acrylic incubator housing and a Nikon NP-2 incubator for
temperature control, coupled to a Dage-MTI CCD-72S camera and a JVC
BR-9050U time lapse video cassette recorder. Plates were incubated at 371C
for 24 h. Images from a randomly selected ¢eld were recorded on videotape
during the incubation period. Selected individual frames were transferred
to a dedicated Macintosh Quadra 800 computer using Adobe PhotoShop.
Aldus Superpaint and NIH Image software are applied to measure the
distances traveled by individual cells (mm nuclear displacement/24 h).
Agarose droplet assay Cell migration on ¢bronectin and FN-120 was also
quanti¢ed using the agarose droplet method of Varani et al (1978). Brie£y,
Immulon I 96-well plastic plates (Dynatech Laboratories, Chantilly, VA)
were coated with ¢bronectin or FN-120 at various concentrations by drying
overnight. The plates were then blocked with 2% BSA, rinsed with PBS,
and dried. Cells were harvested and resuspended in serum-free growth med-
ium containing 0.2% low-gelling-temperature agarose (FMC BioProducts,
Rockland, ME) at a concentration of 3.3107 cells/mL. Droplets (1.5 mL)
of this cell suspension were carefully placed onto the Immulon I-pre-coated
plates. After the agarose droplets were gelled by incubation at 41C for 5 min,
serum-free growth medium with 2% BSA was added with care to avoid
detachment of the droplets. Cells were cultured at 371C in 5% CO2 for
24 h and then ¢xed with 2% glutaraldehyde, stained with crystal violet, de-
stained in water, and air-dried.The outer perimeter of the radially migrating
cells was digitized using a dissecting microscope connected to a computer.
Using NIH Image software the total areas of cell outmigration was calcu-
lated. The baseline area of each agarose droplet was also quanti¢ed and sub-
tracted from the outmigration area to assess the net area of outmigration.
Fibronectin reduction and alkylation Fibronectin was reconstituted
in 3 mL of 8 M urea, 0.5 M Tris-HCl, pH 8.3, and reduced by incubation
for 30 min at room temperature with 40 mg of dithioerythritol (Sigma).
Next 240 mg iodoacetic acid was added to alkylate the reduced ¢bronectin
and the sample was incubated for 30 min at room temperature
(Skorstengaard et al, 1982). The solution was extensively dialyzed against
sterile PBS. The monomeric state of reduced and alkylated ¢bronectin
was con¢rmed on 6% SDS^PAGE run in nonreducing bu¡er.
Recombinant ¢bronectin fragments III1-6, CHep, and Hep were
expressed in bacteria as fusions with maltose-binding protein (MBP) as
previously described (Aguirre et al, 1994). Plasmids encoding MBP-CHepV
and MBP-HepV were constructed using the vector pMALcRI (New
England Biolabs, Beverly, MA). The alternatively spliced V region
nucleotide sequence of ¢bronectin contains three closely spaced arginine
codons of the sequence AGG/A (amino acid positions 2160, 2162, and
2164). tRNAs that recognize these codons are very rare in Escherichia coli.
To improve translation of V-containing fusion proteins, these three
codons were changed to CGA/T codons using degenerate oligonucleotides
in combination with primers homologous to £anking ¢bronectin
sequences for PCR ampli¢cation of the V region. The resulting PCR
product extended from a BamHI site at position 6092 to a XbaI site
engineered at position 6860 (Aguirre et al, 1994). Its sequence was
con¢rmed using Sequenase (US Biochemical, Cleveland, OH). This
fragment was then inserted into pMALcRI-CHep and pMALcRI-Hep to
yield pMALcRI-CHepV and pMALcRI-HepV, respectively. Plasmids were
used to transform E. coli strain TB1. Fusion protein expression was induced
and lysates were prepared as suggested by New England Biolabs.
Preparation of deletions and mutations within the Hep domain (RR/
TM, III13a, -III13b14a, -III14b) have been previously described (Barkalow
and Schwarzbauer, 1994). RR/TM changes a pair of arginine residues to
threonine and methionine; this mutation ablates heparin binding. ^13a
removes residues 7^41 of repeat III13. ^13b14a deletes residues 44^90 of
III13 and 1^39 of III14. ^14b removes amino acids 82^90 of III14 and 1^4
of III15. Restriction fragments containing each of these mutations were
inserted into pMALcRI-CHep or pMALcRI-Hep plasmids as indicated.
Fusion proteins were expressed in E. coliTB1.
MBP-III1-6, MBP-CHep, MBP-CHep (RR/TM), and deletion mutants
were puri¢ed by amylose resin a⁄nity chromatography. MBP-CHepV,
MBP-HepV, and MBP-Hep fusion proteins were puri¢ed by precipita-
tion with 35% ammonium sulfate followed by heparin^agarose a⁄nity
chromatography (Aguirre et al, 1994). Protein purity was checked by
SDS^PAGE.
RESULTS
During tissue healing, ¢brin/¢bronectin bridges appear to
connect periwound stroma to the ¢brin-laden wound
directly before ¢broblast invasion In tissue repair there is a
3-d delay between injury and ¢broblast invasion of the ¢brin
clot-¢lled wound (Clark, 1996). In porcine cutaneous wounds,
¢brinogen and ¢bronectin accumulated in the periwound
stroma on the third day after injury forming a conduit between
collagenous ¢brous septae in the subcutaneous connective tissue
and the ¢brin clot in the wound space (Fig 1). One-day wounds
(Fig 1A,C,E) showed a well-de¢ned boundary between the
¢brin clot in the wound and the underlying subcutaneous tissue.
Furthermore, the ¢brous septae within the subcutaneous tissue
showed tightly packed collagen bundles without obvious cell
in¢ltrate or £uid extravasation. In contrast, 3-d wounds
(Fig 1B,D,F) showed extravasated £uid as well as ¢bronectin
(Fig 1B) and ¢brin (Fig 1D) intercalated between adipocytes in
proximity of the wound space and between collagen bundles in
proximal ¢brous septae. Because ¢broblasts do not invade the
¢brin clot in a wound until 4 d after injury (McClain et al,
1996), the presence of the ¢brin/¢bronectin bridges between the
collagenous dermis and ¢brin clot may be critical for the cell
in£ux. Our recent in vitro observations that ¢bronectin is
required for human dermal ¢broblast transmigration from a
collagenous matrix into a ¢brin clot supports this contention
(Greiling and Clark, 1997).
The RGD containing FN-120 fragment of ¢bronectin
supports initial adult dermal ¢broblast attachment and
spreading but does not sustain it The carboxy-terminal half
of ¢bronectin contains three major domains that can mediate
cell^¢bronectin interactions. To determine the contributions of
the cell (C or FN-120), heparin (Hep), and IIICS (V) domains to
attachment and migration of human adult dermal ¢broblasts,
a variety of proteolytic and recombinant fragments were used
(Fig 2). These proteins contained the cell-binding domain alone
(FN-120), the heparin-binding domain alone (Hep), or com-
binations of two or more domains (CHep, HepV, CHepV).
The cell-binding domain is abbreviated C when it was
generated as a recombinant protein and FN-120 when it was
generated from proteolytic cleavage of plasma ¢bronectin.
CHep-RR/TM is equivalent of CHep but with a pair of Arg
residues mutated toThr and Met in repeat III13. These mutations
ablate heparin binding activity (Barkalow and Schwarzbauer,
1991). III1-6 contained none of the cell interactive domains and
acted as a negative control.
As a ¢rst step toward understanding the role of these domains
in ¢broblast motility, we investigated their ability to mediate
¢broblast attachment in an 1-h assay. Human adult dermal
¢broblasts had optimal attachment for intact ¢bronectin when
coated on plastic at a concentration of 30 mg/mL (120 nM) (Fig 3)
(dose response was performed from 1 to 100 mg/mL but is not
shown). Surfaces coated with 120 nM CHepV or CHep-RR/TM
had the same adhesivity for ¢broblasts as intact ¢bronectin.
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CHep promoted somewhat less adhesive activity (Fig 3). By itself
the Hep was non adhesive for ¢broblasts. FN-120 at 15 mg/mL
(120 nM) promoted 70% attachment (Fig 3) and at 30 mg/mL
(400 nM) promoted 90% attachment (not shown). Spreading
and focal contact formation of ¢broblasts on FN-120 was similar
to intact ¢bronectin at 4 h (Fig 4A and B,C and D, respectively)
and at 8 h (not shown). By 12 h, however, ¢broblast spreading and
focal contact formation on FN-120 became less robust (Fig 4E,F)
than on intact ¢bronectin (Fig 4G,H). By 24 h ¢broblasts plated
on FN-120 began to collapse into a spindle-shaped morphology
with less distinct actin bundles and a relative paucity of focal
contacts (Fig 4I,J). In contrast, ¢broblast on intact ¢bronectin
appeared more spread at 24 h than at 4 h (Fig 4K,L).
Experiments with primary ¢broblasts plated on the recombinant
CHepV protein demonstrated that actin bundle arrays and focal
contact formation was indistinguishable from those formed in
primary ¢broblast plated on intact ¢bronectin at 2, 4, 8, 12, and
24 h (data not shown). Thus, the relatively good initial ¢broblast
attachment and spreading on FN-120 dissipated over a 24-h
incubation, whereas attachment and spreading on intact FN was
sustained.
FN-120 does not support adult human ¢broblast
migration Next we investigated whether PDGF-stimulated
adult human ¢broblasts could migrate from a contracted
collagen gel (a dermal organotypic construct) over surfaces
coated with either intact ¢bronectin or FN-120. Despite
supporting nearly equivalent initial attachment and spreading
compared to intact ¢bronectin (Figs 3, 4), FN-120 did not
support ¢broblast migration at any concentration between 1 and
400 nM (400 nM shown in Fig 5). In contrast, robust migration
was observed on intact ¢bronectin (Fig 5). Reduction and
alkylation of ¢bronectin dimer to the monomeric state did not
a¡ect the ability of ¢bronectin to support either attachment or
PDGF-BB-stimulated migration (data not shown).
To further explore whether primary adult human ¢broblasts
could move on FN-120, cells were plated directly onto FN-120-
coated plastic wells and observed with videomicroscopy for 24 h
at 371C (Table I).Whereas intact ¢bronectin supported baseline
¢broblast motility, FN-120 did not. Neither phorbol 12-myristate
13-acetate nor PDGF-BB was able to stimulate substantial cell
movement on FN-120 whereas both increased ¢broblast
migration on intact ¢bronectin. Additionally, normal adult
human mesenchymal cell migration was studied using the
agarose droplet assay (Varani et al, 1978). None of seven strains of
adult primary human dermal ¢broblasts nor four strains of adult
primary human smooth muscle cells could migrate out of an
agarose droplet over a surface coated with FN-120 in the
absence or presence of PDGF-BB (data not shown). In contrast,
all strains of adult ¢broblasts and smooth muscle cells showed
robust movement on intact ¢bronectin using this assay. To
determine whether the FN-120 preparation used in our assays
could support the movement of any cell type, we investigated
the motility of HT-1080 ¢brosarcoma cells and human neonatal
¢broblasts. Both immortilized ¢brosarcoma cells and neonatal
¢broblasts moved approximately the same distance over FN-120
as they did over intact ¢bronectin (data not shown). These results
are in concert with those previously reported by Nagai et al (1991)
and byAkiyama et al (1989), respectively.
Optimal ¢broblast migration on ¢bronectin requires the cell
and heparin-binding domains and the variably spliced IIICS
domain The Hep, composed of the 12, 13, and 14 type III
repeats adjacent to the carboxy-terminus of FN-120 (Fig 2), was
examined for its contribution to adult human ¢broblast motility.
Fibroblast migration on plates coated with Hep was less than
20% of the migration observed on intact ¢bronectin (Fig 6).
Coating plates with a combination of FN-120 fragments and
recombinant Hep protein, which together presented the cell-
and heparin-binding domains in a noncontiguous array, sup-
ported ¢broblast migration to approximately 45% of the maxi-
mum level observed with intact ¢bronectin (Fig 6). Recombinant
CHep protein, which contains contiguous cell- and heparin-
binding domains in one molecule (Fig 2), supported migration
to approximately 55% of the maximum (Fig 6). Thus, similar
levels of migration occurred whether the cell- and heparin-binding
domains were contiguous or noncontiguous. In contrast, neither
FN-120 fragment alone, nor the control recombinant III1-6 protein
without any known cell-binding sites (Fig 2), allowed any
migration (Fig 6).
To test the role of the IIICS segment (V), which contains cell-
binding sites for a4b1 integrin, recombinant HepV and CHepV
were used for migration assays. As shown in Fig 6, HepV
supported 40% maximal migration, whereas HepV plus FN-120
supported migration comparable to that of intact ¢bronectin.
Essentially the same result was obtained with recombinant
CHepV. In summary, maximal levels of PDGF-stimulated
¢broblast migration were only observed when the RGD cell-
binding domain, the heparin-binding domain, and the IIICS
domain, were available on a surface, regardless of whether the
domains were in a contiguous or noncontiguous array.
Heparin-binding activity is required for ¢broblast
migration Involvement of the heparin-binding domain raises
the possibility that interactions with glycosaminoglycans might
Figure1. Photomicrographs of day 1 (A,C,E) and day 3 (B,D,F) por-
cine wounds stained immunohistochemically for the detection of
¢bronectin (A,B) and ¢brinogen (C,D). Adjacent tissue section were
incubated with nonimmune IgG antibodies for controls (E,F). Arrows, bor-
der between the wound (above) and the subcutaneous tissue (below). At day
1, FN (A) and ¢brinogen (C) are only detectable in the wound area (area
above the arrows, red) but not in the subcutaneous tissue and ¢brous septae. In
contrast, at day 3 ¢bronectin (B) and ¢brinogen (D) are both found in the
wound space as well as in the subcutaneous tissue. (E) and (F) are negative
controls for day 1 (E) and day 3 (F) in which the ¢rst antibody was substi-
tuted by nonimmune rabbit IgG. Bar, 500 mm.
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be important for adult dermal ¢broblast migration on
¢bronectin. To examine this possibility, uncharged amino acids
were substituted for the arginine-pair (RR) in repeat III13
of CHep (CHep-RR/TM). Heparin and chondroitin sulfate
interactions were eliminated by this substitution as previously
described (Barkalow and Schwarzbauer, 1991) and adult dermal
¢broblast migration was completely abolished compared to
approximately 50% maximal migration on nonmutated
recombinant protein CHep and maximal migration on intact
¢bronectin (not shown). In contrast to its inability to support
migration, CHep-RR/TM supported ¢broblast attachment at
levels comparable to intact ¢bronectin (Fig 3).
To test whether other short sequences within the heparin
domain were required for cell mobility, deletion mutants of the
domain were constructed. Hep-13a, Hep-13b14a, and Hep-14b
were missing selected sequences of amino acids in repeats
III13 and III14 (Barkalow and Schwarzbauer, 1991). Hep and
its mutants supported little migration by themselves at
concentrations up to 400 nM (Table II). FN-120 in combination
with Hep, however, supported migration just short of 50% that
observed on intact ¢bronectin, whereas FN-120 addition to
the Hep deletion mutants supported little, if any, migration
(Table 2). Interestingly, the Hep-13a mutant, which deletes a
segment including the RR pair, supported the least migration.
These results taken together clearly indicate that multiple
regions within the heparin domain are required for optimal
adult dermal ¢broblast migration and that the RR pair in repeat
III13 is particularly important.
Maximal ¢broblast migration on ¢bronectin requires
a4b1 Involvement of the variable IIICS domain, as well as the
heparin domain, raises the possibility that a4b1 might be
important for adult human ¢broblast migration on ¢bronectin.
Whereas a5b1 and avb3 both bind ¢bronectin at the RGD cell-
binding site (Ruoslahti, 1988), a4b1 binds ¢bronectin at several
additional sites: the carboxy-terminus of the heparin-binding
domain (Mould and Humphries, 1991) and the CS1 (Komoriya
et al, 1991) and CS5 (Mould et al, 1991) peptide sequences in the
IIICS domain. We previously showed that adult human
¢broblasts expressed functional a4b1 (Gailit et al, 1993). As
demonstrated by Fig 7, monoclonal antibody P4G9 against the
integrin a4 subunit inhibited ¢broblast migration on intact
¢bronectin approximately 50%, whereas anti-HLA monoclonal
antibody HLA and P1B5 to a3 subunit (not shown) had no
e¡ect. P4G9 also inhibited migration of adult human ¢broblast
on CHep about 50%.
Figure 2. A diagram showing the domain organization and modular structure of the plasma ¢bronectin dimer is shown at the top. Fibronec-
tin fragments and recombinant proteins used in this study are aligned with corresponding ¢bronectin repeats in the intact molecule. Small rectangles, ¢bro-
nectin type I repeats; ovals, ¢bronectin type II repeats; squares, ¢bronectin type III repeats (Yamada and Clark, 1996). FN-120 is a proteolytic fragment of
¢bronectin. III1-6, CHepV, HepV, CHep, and Hep were expressed in bacteria as fusions with MBP (Barkalow and Schwarzbauer, 1991; Aguirre et al, 1994).
V, an alternatively spliced variant which contains the IIICS region.
Figure 3. Fibroblast attachment to ¢bronectin, 120-kDa ¢bronectin
fragment containing the RGD cell-binding domain (FN-120), and
recombinant ¢bronectin moieties. CHep-RR/TM contains the RGD
cell-binding and heparin domains with mutations of the RR pair in repeat
III13 to Thr-Met as previously described (Barkalow and Schwarzbauer,
1991). Proteins were coated on the assay plates by drying 120 nM solutions
overnight at room temperature. Plates were blocked with 2% BSA and
washed, and then 10,000 ¢broblasts per well were added. After incubation
for 1 h, attached cells were ¢xed with 2% glutaraldehyde and stained with
0.1% crystal violet. Absorbance of solubilized crystal violet was measured
at 590 nm with a dual-wavelength, microtiter plate reader (THERMO-
max, Molecular DevicesCA). Experimental conditions were run in tripli-
cate and data are displayed as means7SD.
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Biologically active synthetic peptides constructed from
sequence arrays within the heparin- and IIICS-binding
domains block ¢broblast migration on ¢bronectin To
further de¢ne which heparin and IIICS subdomains are involved
in adult dermal ¢broblast migration on ¢bronectin, synthetic
peptides were manufactured from sequences known to interact
with cells in repeats III12, III13, and III14 (peptides III, IV, V, I,
and II, respectively) and the IIICS segment (CS1 and CS5)
(Fig 8).When added to the outmigration assay, peptides III, IV,
Figure 4. Fibroblast spreading and focal contact formation on FN-120 (A and B,E and F,I and J) and intact ¢bronectin (C and D,G and H,K and
L). Fibroblasts were incubated in protein-coated Lab-Tec chambers with DMEM and 2% albumin for 4 (A^D), 12 (E^H), or 24 (I^L) h at 371C and then
¢xed, permeabilized, and stained for vinculin with mouse monoclonal antibody and secondary FITC-anti-mouse IgG (A,C,E,G,I,K) and for actin with
TRITC-phalloidin (B,D,F,H,J,L). Bar, 5 mm.
Figure 5. Fibroblast migration on intact ¢bronectin and FN-120. An
organotypic construct of human dermal ¢broblasts in collagen gels con-
taining 30 mg/mL ¢bronectin was pasted on tissue culture dishes coated
with ¢bronectin or FN-120 as previously described (Greiling and Clark,
1997). Cultures were incubated for 24 h in medium containing 30 ng/mL
PDGF-BB. The nuclei of cells that had migrated out of the collagen gels
were counted visually. Each histogram represents the mean7SD of cells
migrating out of triplicate constructs.
Table I. Fibroblast movement on intact ¢bronectin
and FN-120
Experimental condition
Substrate Additional stimulus
Cell movement
(mm/24 h)
Intact ¢bronectina None 27879.9b
Intact ¢bronectin PDGF-BB (30 ng/mL) 46979.8
Intact ¢bronectin PMAc (300 ng/mL) 479710.0
FN-120 None 070
FN-120 PDGF-BB (30 ng/mL) 979
FN-120 PMA (300 ng/mL) 974
aPlates were prepared and cells added as described in (Fig 2B).
bMean7SD, n¼ 4.
cPMA, phorbol 12-myristate 13-acetate.
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V, I, and II inhibited the migration of ¢broblasts over ¢bronectin
in a concentration-dependent manner (Fig 9). CS1 had a slight
enhancing e¡ect at higher concentrations, whereas CS5 did
not in£uence migration at tested concentrations. A scrambled
peptide of CS1 (CS1i) used as a control did not in£uence
migration. To determine whether the observed e¡ect of
synthetic peptides on the migration was speci¢c for ¢bronectin,
collagen-coated assay plates were substituted for ¢bronectin
coated plates. Peptides III, IV, and V had no e¡ect on migration
over collagen, whereas peptides I and II had an inhibitory e¡ect
in a concentration-dependent manner. CS1 enhanced the
migration at higher concentrations, whereas CS1i did not
in£uence the activity.
The ability of peptides I and II to inhibit adult human
¢broblast migration on both ¢bronectin and collagen raises the
possibly of nonspeci¢city, especially because peptides I^V have
a net positive charge. Therefore, we constructed scrambled
controls of peptides I^V. Furthermore, because peptide IV
(SPPRRARVT) contains the heparin-binding RR pair, LL was
substituted for RR (SPPLLARVT) in an additional peptide IV
control. As shown in Fig 10, peptides I^V (Fig 10, open squares)
inhibited adult human ¢broblast migration on intact ¢bronectin,
whereas scrambled controls (Fig 10, closed squares) did not.
Interestingly, the peptide IV derivative carrying the LL
substitution for RR (Fig 10, crossed triangle) did not inhibit
except modestly at the highest concentration. These data taken
Figure 7. P4G9 monoclonal antibody to a4 inhibits ¢broblast
migration on intact ¢bronectin (FN) and the recombinant protein
containing the cell and heparin binding domains (CHep). The out-
migration assay as described in the legend to Fig 6 was allowed to proceed
for 24 h in the presence or absence of monoclonal antibodies and then the
migrated cells were visually counted. Experimental conditions were run in
triplicate, and data are displayed as means7SD. All data were normalized
to maximum migration on intact ¢bronectin in the absence of antibodies.
Controls included mouse monoclonal anti-HLA and mouse monoclonal
P1B5 to a3-integrin subunit neither of which inhibited movement (data
not shown).
Figure 8. Localization of peptide sequences within the heparin and
IIICS domains. III, IV, V, I, II, CS1, and CS5 indicate sites of sequence
arrays used to model synthetic peptides. CS/H, HS, and a4b1 indicate pu-
tative binding sites for chondroitin sulfate, heparin, heparan sulfate, and the
integrin receptor a4b1, respectively.
Figure 6. Fibroblast migration on intact ¢bronectin (FN), frag-
ments of ¢bronectin containing the RGD cell-binding domain
(FN-120), and recombinant RGD cell-binding (C), heparin (Hep),
and IIICS domains (V) of ¢bronectin. Assay plates were coated with
4^400 nM FN-120 or recombinant proteins as described under Methods.
The coating e⁄ciency of all proteins was essentially the same as judged by
the bicinchoninic acid protein assay (Tuszynski and Murphy, 1990). After
blocking with 2% BSA, organotypic constructs of ¢broblasts in a collagen
gel containing ¢bronectin and PDGF-BB were pasted onto the protein-
coated assay plates. DMEM containing 2% BSA and 30 ng/mL PDGF-
BB was added so that the £uid level was even with the top of the collagen
gel. Fibroblasts that had migrated over the protein-coated surface after a
24-h incubation were quanti¢ed by visual counting. All experimental con-
ditions were run in triplicate, and data are displayed as means7SD. All
data were normalized to maximum migration of intact ¢bronectin.
Table II. Fibroblast migration on Hep and its deletion
mutants
Deletion mutants Without FN-120 With FN-120
Fibronectina 10072.7b ND
Hep 15.371.1c 45.471.1
Hep-13a 6.372.4 8.774.8
Hep-13b14a 23.371.7 23.372.2
Hep-14b 20.172.0 1573.7
aAll proteins were assayed at concentrations from 3 to 400 nM; however, max-
imum ¢broblast migration was observed when 120 nM protein was added to assay
plates. Therefore, the data shown were acquired from plates coated with 120 nM
¢bronectin, recombinant proteins or FN-120.
bFibroblast migration on ¢bronectin was normalized to 100%.
cData are presented as means7SD percentage of migration of that observed on
¢bronectin. All conditions were run in triplicate.
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together indicate that sequence is important for function of these
peptides.
The apparent lack of inhibitory e¡ect of CS1 and CS5 on
¢broblast movement on ¢bronectin (Fig 9) was surprising
because the presence of the IIICS domain (V) was required for
maximal migration (Fig 6). Therefore, CS1 and CS5 synthetic
peptides were added to the migration assay together. As shown
in Fig 11, when present concomitantly, CS1 and CS5 inhibited
migration in a concentration-dependent fashion.
Synthetic peptides block ¢broblast invasive migration into
¢brin gels To determine whether the results obtained from the
two-dimensional outmigration assay related to more complex,
three-dimensional transmigration, the same synthetic peptides
were added to the ¢brin/¢bronectin gel in the transmigration
assay as previously described (Greiling and Clark, 1997). All
peptides, except peptide III, gave essentially the same results
(data not shown). Surprisingly, peptide III had no e¡ect on
¢broblast transmigration from collagen matrix into a three-
dimensional array of ¢brin and ¢bronectin, which is in contrast
to its ability to completely inhibit migration over a two-
dimensional ¢bronectin coat (Fig 10). To determine whether the
interaction of ¢brin with ¢bronectin might have led to the
apparent discrepancy between transmigration and outmigration,
assay plates were coated with ¢bronectin in the presence of
dried ¢brin ¢brils. Migration over two-dimensional dried
¢brin/¢bronectin ¢brils was also not in£uenced by peptide III
(data not shown). Therefore, interactions between ¢brin and
¢bronectin may have abrogated the ability of peptide III to
inhibit migration.
DISCUSSION
The data presented in this report demonstrate that three
¢bronectin molecular domains, the RGDS cell-binding, the
Figure 9. Synthetic peptides III, IV, and V from the heparin-bind-
ing domain inhibit ¢broblast migration on ¢bronectin, but not on
collagen substratum. Assay plates were coated with either 120 nM ¢bro-
nectin (open triangles) or collagen (closed triangles) as described under Meth-
ods. Synthetic peptides (III, IV,V, I, II, CS1, CS5, and control peptide CS1i)
were added at the concentrations shown to assay medium (DMEM, 2%
BSA) in the presence of 30 ng/mL PDGF-BB. Fibroblasts that had mi-
grated over the protein-coated surface after a 24 -h incubation were quanti-
¢ed by visual counting. All data were normalized to maximum migration
of intact ¢bronectin without addition of synthetic peptides (closed circle). No
migration was observed on ¢bronectin without PDGF-BB (not shown).
All experimental conditions were run in triplicate, and data are displayed
as means7SD.
Figure10. Synthetic peptides from the heparin-binding domain,
but not related scrambled peptides, inhibit ¢broblast migration on
¢bronectin. Assay plates were coated with 120 nM ¢bronectin. Synthetic
peptides III, IV,V, I, and II (open squares), scrambled variants (closed squares),
or a LL substitution for RR in peptide IV (crossed triangle) were added at the
concentrations shown to assay medium (DMEM, 2% BSA) in the present
of 30 ng/mL PDGF-BB. Fibroblasts that had migrated over ¢bronectin
coated surface after a 24 -h incubation were quanti¢ed by visual counting.
All data were normalized to maximum migration of intact ¢bronectin
without addition of synthetic peptides (closed circles). No migration was ob-
served on ¢bronectin without PDGF-BB (not shown). All experimental
conditions were run in triplicate, and data are displayed as means7SD.
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heparin-binding, and the alternatively spliced IIICS domains, are
necessary and su⁄cient for optimal migration of primary human
¢broblasts on ¢bronectin. In fact, multiple strains of normal hu-
man ¢broblasts and smooth muscle cells failed to migrate on FN-
120, a fragment containing the classic RGDS cell-binding site
and the PHSRN synergy site. This is in marked contrasted to
the ability of certain human ¢brosarcoma cell lines (HT 1080) to
migrate on FN-120 and on even smaller subfragments of FN-120
(Akiyama et al, 1995) or rat NR6 cells ability to migrate
of RGD nanoscale clusters (Maheshwari et al, 2000). Likewise
involuting marginal zone cells from a Xenopus embryo migrate
on fusion proteins containing the RGD and synergy site se-
quences PHSRN (Ramos and DeSimone, 1996). The studies of
HT 1080 (Akiyama et al, 1989; Nagai et al, 1991; Akiyama et al,
1995), NR6 cells (Maheshwari et al, 2000), and involuting mar-
ginal zone cell (Ramos and DeSimone, 1996) migration on
RGD clusters or RGD-containing ¢bronectin fragments, in fact,
have led some investigators to extrapolate that ¢broblasts, in gen-
eral, only need the ¢bronectin cell-binding domain for migra-
tory activity (Ramos and DeSimone, 1996).
FN-120 supported initial attachment of adult human ¢bro-
blast, albeit suboptimally compared to intact ¢bronectin or
recombinant CHepV, but could not support sustained spreading.
The inability of ¢bronectin fragments containing only the RGD
cell-binding site to support actin stress ¢ber and focal contact
formation was ¢rst reported in human embryonic ¢broblasts
15 y ago (Woods et al, 1986). In that report Woods et al demon-
strated that the heparin domain was required for such cytoskeletal
organization. More recently, investigators using ¢broblast cell
lines (MG-63, Rat1, and NIH 3T3 cells) found that actin bundles
and focal contacts were not well formed on FN-120 or a recom-
binant ¢bronectin containing the 7^11 type III repeats (called FN
7^11) even at 2 h (Bloom et al, 1999). Our data with primary hu-
man adults dermal ¢broblasts di¡er from both of these studies in
that actin stress ¢bers and focal contacts are formed when cells are
plated on FN-120 for up to 8 hr, but this ¢bronectin fragment
containing the RGD cell-binding domain alone cannot sustain
cytoskeletal organization.
Previously we demonstrated that the RGDS cell-binding
peptide within FN-120, and that a5b1 and avb3 integrins, which
bind FN-120 through the RGDS site, were required for ¢broblast
migration over ¢bronectin (Greiling and Clark, 1997). These data
taken together with the results presented here predict that the
FN-120 fragment is necessary, but not su⁄cient, for the move-
ment of normal adult human ¢broblasts over ¢bronectin. Thus,
other ¢bronectin domains that promote attachment and/or mi-
gration of other cells were examined for their ability to support
adult human ¢broblast migration.
Hep interacts with at least two distinct classes of cell surface
receptors: a4b1 integrin receptors and heparan sulfate and chon-
droitin sulfate glycosaminoglycans found on cell surface pro-
teoglycan receptors (McCarthy et al, 1990; Barkalow and
Schwarzbauer, 1991, 1994; Drake et al, 1992; Iida et al, 1992;Woods
et al, 1993). Recombinant Hep protein alone supported only 20%
maximal migration, but CHep or Hep plus FN-120 supported
migration to approximately 55% maximum. Thus, half-maximal
migration occurred whether the RGD cell- and heparin-binding
domains were contiguous or noncontiguous. Similarly, heparin-
binding repeat III13 plus cell-binding repeats III7^11 were found
necessary and su⁄cient for actin bundle and focal contact forma-
tion regardless of their spatial relationship to each other (Bloom
et al, 1999).
Deletion mutants within the Hep domain indicate that repeats
III13 and III14 were both involved in adult human ¢broblast mi-
gration.These two repeats have also been implicated in formation
of focal contacts. Repeat III13 in conjunction with a recombinant
cell-binding domain was able to induce actin bundles and focal
contacts in ¢broblast cell lines (Bloom et al, 1999). A peptide
(WQPPRARI) from repeat III14 was shown to promote focal at-
tachment formation in primary human embryonic ¢broblasts
(Woods et al, 1993). In vitro binding assays have shown that both
repeats III13 and III14 contribute to heparin-binding activity (Ing-
ham et al, 1993). The discontinuity of residues involved in heparin
binding has been con¢rmed by structural modeling studies (Bus-
by et al, 1995). Therefore, it is not surprising that multiple sites
within the heparin-binding domain participate in this process.
At least ¢ve peptide sequences have been implicated in cell
interactions with the heparin domain (McCarthy et al, 1988; Iida
et al, 1992). Peptide III from repeat III12 is functional in melanoma
cell binding to ¢bronectin (Iida et al, 1992). Peptide IV from
repeat III13 promotes rabbit corneal epithelial cell attachment
and spreading (Mooradian et al, 1993). Peptide V from repeat
III14 promotes multiple cell activities including rabbit corneal
epithelial cell attachment, spreading, and migration (Mooradian
et al, 1993); focal contact formation in human embryonic ¢bro-
blasts (Woods et al, 1993); human keratinocyte attachment and
spreading (Wilke et al, 1993); endothelial cell spreading and
migration (Huebsch et al, 1995); and rabbit synovial ¢broblast
expression of MMPs (Huhtala et al, 1995). Peptides I and II from
repeat III14 also mediate attachment and spreading of melanoma
cells (McCarthy et al, 1988, 1990), human keratinocytes (Wilke
et al, 1991) and rabbit corneal epithelial cells (Mooradian et al,
1992).
All of these peptides inhibited primary ¢broblast migration
on ¢bronectin, whereas the scrambled peptides had no e¡ect.
Figure11. CS1 and CS5 peptides conjointly inhibit ¢broblast mi-
gration on ¢bronectin. (Top) In the presence of 100 mMCS1 cell-binding
peptide, the CS5 cell-binding peptide progressively inhibits ¢broblast mi-
gration on ¢bronectin with concentrations up to 100 mM (closed triangles).
By itself 100 mMCS1 had no e¡ect of migration (closed circle). (Bottom) Like-
wise, in the presence of 100 mM CS5 cell-binding peptide, the CS1 cell-
binding peptide progressively inhibits migration with concentrations up
to 100 mM (closed triangles). By itself 100 mMCS5 had no e¡ect of migration
(closed circle).
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Surprising to us, peptides I and II also inhibited ¢broblast migra-
tion on type 1 collagen. These two peptides, however, can bind
chondroitin sulfate proteoglycans (Iida et al, 1992), and a CD44-
related chondroitin sulfate proteoglycan is required for melanoma
cell motility on type 1 collagen (Faassen et al, 1993). The need for
intact heparin domain type III repeats 12^14 and the almost com-
plete inhibition of migration by a variety of heparin domain
peptides suggest that a high degree of cooperativity must occur
within the heparin domain for proper receptor interaction. The
three-dimensional structure of the heparin domain, in fact, pre-
dicts that this might be so (Sharma et al, 1999).
In addition to the cell- and heparin-binding domains, the vari-
able IIICS is also required for maximal ¢broblast migration.
Within this segment are CS1 and CS5 peptide sequences that
bind a4b1 integrin (Komoriya et al, 1991; Mould et al, 1991).
Recombinant protein containing cell, heparin, and IIICS do-
mains supported migration comparable to intact ¢bronectin.
Furthermore, maximal ¢broblast migration was observed regard-
less of whether cell, heparin, and IIICS domains were contiguous.
These data taken together indicate that multiple receptors inter-
acting with multiple sites on ¢bronectin are needed for adult
human ¢broblast migration.
Previously, we demonstrated that both a5b1 and avb3 are
required for human ¢broblast migration (Greiling and Clark,
1997). The ability of P4G9 anti-a4 antibody to inhibit human
dermal ¢broblast migration on ¢bronectin, albeit weakly, indi-
cates that a4b1 is also necessary for optimal human ¢broblast
motility. These data are in concert with observations that activa-
tion of the a4 cytoplasmic tail is required for rhabdomyosarcoma
cell movement (Chan et al, 1992). Other cell lines, such as mela-
noma cells (Humphries et al, 1986; Mould et al, 1994) and murine
S180 cells transfected with a4b1 (Beauvais et al, 1995), have the
capacity to migrate on isolated IIICS domain using a4b1 integ-
rin. a4b1 binds IIICS at two sites, CS1 (Komoriya et al, 1991) and
CS5 (Mould et al, 1991), and more weakly binds the heparin do-
main near its carboxy-terminal end (Mould and Humphries,
1991). The ability of anti-a4b1 antibodies to partially inhibit
¢broblast migration on fragments lacking IIICS suggests that
the heparin-binding site for a4b1 may be functional. That CS1
and CS5 synthetic peptides added singly fail to block ¢broblast
migration suggests that a4b1may use any one of its various bind-
ing sites on ¢bronectin alternatively to promote movement.
Taken together, our data demonstrate that a minimum of three
integrin receptors are needed for maximal adult human ¢broblast
migration on ¢bronectin.
The heparin domain requirement raises the possibility that one
or more proteoglycan receptor(s) may be needed for adult human
¢broblast motility. Two such receptors have been identi¢ed:
a dermatan sulfate CD44 proteoglycan (Clark et al, 2003) and
syndecan-4 (Lin and Clark, manuscript in preparation). Thus,
the movement of normal human mesenchymal cells is highly
restrained on ¢bronectin necessitating the presence of three
distinct functional domains and the proper complement of
expressed and activated cell surface receptors. Furthermore,
deposits of ¢bronectin may be requisite for movement of
mesenchymal cells in the wounded animal.
This antimigratory characteristic of normal connective tissue
cells may explain, in part, why stromal cells are relatively station-
ary in the absence of architectural boundaries such as basement
membranes. Furthermore, the high stringency for mesenchymal
cell migration on ¢bronectin may explain why tissue cells fail to
repopulate chronic wounds which abound with proteases (Wy-
socki et al, 1993; Grinnell and Zhu, 1994) and demonstrate frag-
mentation and loss of tissue ¢bronectin (Grinnell et al, 1992;
Herrick et al, 1992). Loss of migratory constraint on ¢bronectin
can occur in embryogenesis, as demonstrated by involuting mar-
ginal zone cells (Ramos and DeSimone, 1996), and in malignancy
as evident with ¢brosarcoma (Akiyama et al, 1989, 1995; Nagai
et al, 1991), squamous cell carcinoma (Nagai et al, 1991), and mela-
noma cells (Humphries et al, 1986; Mould et al, 1994). Because
¢bronectin is widely expressed during embryogenesis and widely
deposited at sites of cancer, unconstrained cells would have a road
to move on.
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